A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Unsatisfactory Symptom State (ESSPRI Score ≥ 5)
- Promotore
- Horizon Therapeutics Ireland DAC
- Acronimo
- HZNP-DAZ-303
- Struttura
- Reumatologia
- Sperimentatore principale
- Stobbione Paolo
- Stato arruolamento
- In attesa di arruolamento